CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• CD34 positivity is typically an adverse prognostic factor in acute myeloid leukemia (AML).
• Nucleophosmin 1-mutated (NPM1m) AML usually presents as CD34 negative, but CD34 expression can occur at diagnosis or relapse.
• The prognostic significance of CD34 in NPM1m AML requires clarification.

Purpose of the Study:

• To investigate the influence of CD34 expression on the clinical outcome of adult patients with NPM1m AML.
• To determine if CD34 expression level affects complete remission, relapse rates, disease-free survival, or overall survival in NPM1m AML.

Main Methods:

• Analysis of clinical outcomes in 67 adult patients with NPM1m AML.
• Assessment of CD34 expression levels using flow cytometry at diagnosis and/or relapse.
• Correlation of CD34 expression with complete remissions, relapses, disease-free survival, and overall survival.

Main Results:

• CD34 expression did not significantly influence any of the analyzed clinical outcome variables.
• The percentage of blasts expressing CD34 had no impact on patient prognosis.
• No difference in outcome was observed based on CD34 expression status at diagnosis or relapse.

Conclusions:

• CD34 expression is not an unfavorable prognostic factor in NPM1-mutated AML.
• This contrasts with the established role of CD34 in other forms of AML.
• Clinical management and prognostic assessment of NPM1m AML should not rely on CD34 status.